IACUC Protocol #: G2018-22
Veterinary Speciality: Oncology
The purpose of this clinical trial is to evaluate the activity of new formulation of an old chemotherapy drug called paclitaxel in dogs with mast cell tumors. Paclitaxel is not water soluble and therefore needs to be formulated with a chemical that permits intravenous administration. ART207 is a new formulation of paclitaxel in which the drug is encapsulated in a lipid (fat) protein complex designed to promote specific uptake of the complexes through cholesterol receptors that are expressed in tumors. ART207 results in much higher exposures to paclitaxel than the previous formulations and may have greater anti-tumor activity in dogs with cancer.
The ultimate goal of this clinical trial is to shrink your dog’s tumor by using a novel formulation of paclitaxel that selectively targets the tumor cells, thereby reducing systemic side effects. As paclitaxel is known to have activity against tumors in dogs, it is likely that ART207 will have equivalent or superior activity to paclitaxel given its higher drug exposures.
The study will cover all diagnostics (bloodwork, imaging, biopsies, etc) and treatments (ART207 administration, supportive medications) associated with the tumor while your dog is enrolled in this study as well as the management of any study-related side effects. Except for the specific financial support described here, any tests or procedures unrelated to this study including treatment of conditions unrelated to the mast cell tumor are your responsibility.
For questions regarding the clinical trial please email the clinical trials technician, Diane Welsh at: email@example.com
If you believe that your pet may be eligible for this study, please complete our prescreening questionnaire for owners.